The overall goal of the Leukemia SPORE Developmental Research Program (LSDRP) is to recruit and support developmental research projects in leukemia for future peer-reviewed funding and/or future independent SPORE projects. The types of studies to be supported include projects in basic research, clinical research, epidemiologic studies, and cancer prevention and control research in leukemia. Projects supported under the LSRDP will expand the scope of translational research and increase the number of investigators committed to leukemia research. The LSDRP will work in tandem with the Career Development Program to assist in the development of junior investigators and in the recruitment and mentoring of minority investigators. To accomplish these goals, the following specific aims are proposed 1. To support developmental research projects in leukemia for future incorporation as full SPORE projects and for applications for other major peer-reviewed funding. New research projects will be solicited and funded using developmental funds. A total of $175,000 has been committed annually to this program (including $125,000 per year of matching funds from institutional sources). These funds will be used to support 3-5 developmental projects per year ranging from $30,000 to $60,000 throughout the life of the SPORE. 2. Foster collaborations between basic and clinical researchers. The LSDRP chairs will facilitate interaction between basic and clinical researchers through shared weekly meetings, the annual SPORE retreat, and small group meetings. 3. To provide mentoring to junior faculty. Ail investigators submitting developmental research projects will receive a written scientific and statistical review, and the LSDRP chairs will be available to discuss the projects in detail. Where appropriate, mentors will be identified to work with junior faculty.

Public Health Relevance

The Developmental Research Program will recruit and support innovative early-stage research in leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA171963-02
Application #
8764903
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$79,097
Indirect Cost
$51,269
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:
Monlish, Darlene A; Bhatt, Sima T; Duncavage, Eric J et al. (2018) Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood 131:1032-1035
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Staser, Karl W; Eades, William; Choi, Jaebok et al. (2018) OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. Cytometry A 93:186-189
Warner, Wayne A; Spencer, David H; Trissal, Maria et al. (2018) Expression profiling of snoRNAs in normal hematopoiesis and AML. Blood Adv 2:151-163
Nguyen, Hai Dang; Leong, Wan Yee; Li, Weiling et al. (2018) Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Res 78:5363-5374
Cooper, Matthew L; Choi, Jaebok; Staser, Karl et al. (2018) An ""off-the-shelf"" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32:1970-1983
Wang, Tianjiao; Jacoby, Meagan A; Duncavage, Eric J et al. (2018) Exome analysis of treatment-related AML after APL suggests secondary evolution. Br J Haematol :
Bansal, Dhruv; Vij, Kiran; Chang, Gue Su et al. (2018) Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica 103:e270-e273

Showing the most recent 10 out of 64 publications